If you've been researching weight loss peptides, GLP-1 injections, or peptide therapy, you've probably hit a wall of conflicting information. Here's what's Health Canada approved, what the clinical evidence actually shows, and how an Alberta pharmacist can write the prescription same day, no GP referral.
What weight loss peptides are
Peptides are short amino acid chains, miniature proteins that act as biological messengers. The peptides with the strongest weight-management evidence work on receptors in your gut, pancreas, and brain to modulate appetite, blood sugar, and metabolism.
The category with the best clinical data is GLP-1 receptor agonists, compounds that mimic glucagon-like peptide-1, a hormone your gut releases after eating to signal fullness. These are fully approved pharmaceuticals with the strongest weight-loss trial results ever recorded.
The three Health Canada approved options
Semaglutide (Wegovy / Ozempic)
Weekly subcutaneous injection. Suppresses appetite via the hypothalamus, slows stomach emptying, improves insulin response. STEP 1 trial: 14.9% mean weight loss at 68 weeks. STEP UP at the 7.2 mg dose: 20.7%, with one-third of patients hitting 25%+ body weight loss.
Eligibility: BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition (hypertension, type 2 diabetes, high cholesterol, sleep apnea, cardiovascular disease). Dosing starts at 0.25 mg weekly and titrates to 1.7 to 2.4 mg.
Tirzepatide (Zepbound / Mounjaro)
The newest and most potent option, a dual GIP/GLP-1 receptor agonist that hits two metabolic pathways at once. SURMOUNT-1 at 15 mg: 22.5% mean weight loss. Head-to-head SURMOUNT-5: tirzepatide 20.2% vs. semaglutide 13.7%. Same eligibility as semaglutide. Available in 2.5 to 15 mg weekly doses.
Liraglutide (Saxenda)
The longest-established option in Canada. Daily injection rather than weekly, but the longest safety record and the only one approved for adolescents 12 and older. SCALE trial: 8.4 kg mean weight loss vs. 2.8 kg with placebo at 56 weeks. Dosed 0.6 mg daily, titrated to 3.0 mg.
What about BPC-157, AOD-9604, CJC-1295, ipamorelin?
None of these are approved by Health Canada for human use. In April 2025 Health Canada issued a consumer safety alert against injecting peptides bought online. The College of Physicians and Surgeons of Alberta echoed it. These compounds:
- Have not been assessed for safety, effectiveness, or manufacturing quality
- Are unauthorised drugs under Canadian law
- Are sold under "research use only" labels, which provide no consumer protection
- Carry real risks: bacterial contamination, severe reactions, unknown long-term effects
The approved GLP-1 and GIP/GLP-1 medications above have been tested in tens of thousands of patients. That's the bar that protects patients. We only prescribe medications that meet it.
Side effects to expect
All three medications share a similar profile, mostly gastrointestinal:
- Nausea (~37% of trial participants), most common during dose escalation
- Vomiting (~16%) and constipation (~15%)
- Diarrhea (~13%) and fatigue (~17%)
Effects are usually mild to moderate and transient. They fade as your body adapts. Slow dose titration (start low, go slow) substantially reduces severity. Hydration matters, 2+ litres a day, especially for kidney function and constipation. Most patients who push through the first 2 to 4 weeks have minimal side effects by week 6.
Rare but serious: pancreatitis, gallbladder issues. Your pharmacist will screen for risk factors before prescribing and watch for warning signs throughout.
Who qualifies
- BMI ≥ 30, OR BMI ≥ 27 with at least one of: hypertension, type 2 diabetes, high cholesterol, sleep apnea, cardiovascular disease
- Lifestyle modifications attempted without sufficient result
- Not pregnant or planning pregnancy during treatment
- No personal or family history of medullary thyroid carcinoma or MEN2 syndrome
How a pharmacist prescribes it, no referral
Most Edmontonians don't realise this: in Alberta you don't need a GP referral or a specialist appointment to start. Alberta pharmacists with Additional Prescribing Authorization (APA) can independently assess, prescribe, adjust dose, order labs, and manage you ongoing. Our pharmacist holds APA.
What we look at during the assessment:
- BMI and weight history
- Relevant comorbidities
- Current medications, for interactions and hypoglycemia risk
- Personal goals and prior weight-management attempts
This is a real clinical assessment, equivalent to what a physician would do, with a medication specialist who has time to explain. If appropriate, we write the prescription same day. No waitlist. No referral. Walk in.
Insurance and cost
Coverage varies. Many private plans cover Saxenda, Ozempic, and Mounjaro for qualifying conditions. Wegovy and Zepbound coverage is broadening. Generic semaglutide is expected in Canada later in 2026 and will likely shift the cost picture significantly. We can help you navigate your benefits before you start.
Walk in or call
(780) 443-0202. Unit 103, 15508 87 Ave NW, Meadowlark Place, Edmonton.